Roll

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Roll

Quick Facts

Property Description
Active ingredient Rabeprazole (Rabeprazole sodium)
Form Oral delayed-release tablet or enteric-coated capsule
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Gastric acid suppression
Origin Synthetic, substituted benzimidazole

What Type of Medicine is Roll?

Roll is a prescription-only medicine whose active component is Rabeprazole, often formulated as Rabeprazole sodium, a synthetic compound classified within the major pharmacological class of Proton Pump Inhibitors (PPIs). Rabeprazole is a substituted benzimidazole compound, and its general therapeutic role is to act as a powerful antisecretory agent. Within the PPI class, Rabeprazole is characterized by high bioavailability, an attribute contributing to its reliable effectiveness in acid control. This ensures the medication consistently meets its goal of profoundly and selectively reducing the amount of gastric acid produced by the stomach, making it a foundational tool for the management of various acid-related disorders.


Composition and Physical Form of Roll

The sole active ingredient in Roll is Rabeprazole, which is designed into an oral delayed-release tablet or an enteric-coated capsule dosage form. This specialized composition is crucial because Rabeprazole is highly sensitive to the low pH conditions in the stomach, necessitating protection from gastric acid upon ingestion. The pharmaceutical excipients and the enteric coating ensure the medication remains intact as it travels through the esophagus and stomach before absorption. Unlike immediate-release medications, the delayed-release mechanism of the Roll formulation ensures the drug reaches the intestine before absorption, promoting consistent therapeutic action.


What is the General Purpose of Rabeprazole?

The general purpose of Rabeprazole is to achieve sustained and profound gastric acid suppression by targeting the cells responsible for acid production. It functions as a prodrug, converting to an active molecule that then binds irreversibly to the H+/K+-ATPase enzyme, commonly known as the proton pump. This mechanism of selective inhibition effectively and consistently reduces the acid produced by the stomach, establishing Roll as an antiulcer drug that creates an environment conducive to the healing of the upper gastrointestinal tract.

Regulatory References

  1. Proton Pump Inhibitor (PPI)
  2. World Health Organization (WHO)
  3. before absorption (FDA)

What side effects are possible with Roll?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics of Rabeprazole sodium (Roll) as formally documented in government regulatory sources, such as the FDA and EMA prescribing information. The information is presented neutrally and must not be considered clinical advice.

Frequency-Classified Adverse Reactions

Side effects reported in clinical trials and classified as Common (occurring in 2% of adult patients and greater than placebo) typically involve the Gastrointestinal and Nervous Systems. These commonly listed effects include headache, diarrhea, constipation, flatulence, abdominal pain, and pharyngitis (sore throat).

Serious Adverse Reactions and Duration-Related Risks

Regulatory documents highlight risks associated with both short-term and prolonged exposure. Rare, but clinically significant events include the potential for Acute Interstitial Nephritis (AIN), Severe Cutaneous Adverse Reactions (e.g., SJS, TEN), and an increased risk of Clostridium difficile-associated diarrhea (CDAD). Risks explicitly linked to long-term daily use (e.g., typically over one year) include Hypomagnesemia (low magnesium levels), development of Fundic Gland Polyps, and an increased risk of Bone Fracture of the hip, wrist, or spine.

Population-Specific Safety Notes

The official safety profile contains notes specific to certain patient groups. Use of the delayed-release tablet form is not recommended in children younger than 12 years of age. Caution is advised for individuals with hepatic impairment, as the body's elimination of the medicine may be slower. Additionally, it is noted that a symptomatic response to therapy does not preclude the presence of an underlying gastric malignancy.

Key Safety Constraints

Rabeprazole is contraindicated in patients with a known hypersensitivity to the drug or related benzimidazole compounds. The drug is also contraindicated for co-administration with products containing the antiretroviral rilpivirine.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents provide specific guidance for a suspected overdose of Roll (Rabeprazole). Clinical experience with deliberate or accidental overexposure is limited, and documented effects are generally minimal and reversible without further medical intervention. The clinical signs observed are typically representative of the known adverse event profile rather than unique, severe overdose symptoms.

In the event of overdosage, contact your regional poison control center immediately for management information. Urgent medical help from emergency services is required if the affected individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Management and Constraints

Management must be strictly symptomatic and supportive, as no specific antidote is known for Rabeprazole. Required procedures include the meticulous monitoring and maintenance of essential physiological parameters, such as vital signs, blood gases, and serum electrolytes. Due to the drug’s extensive protein binding, it is officially noted that Rabeprazole is not readily dialyzable, which constrains certain procedural interventions in a severe overdose setting.

Therapeutic Uses of Roll

What Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Treat: Main Uses and Benefits

The primary therapeutic domain for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is related to easing symptoms related to physical discomfort and systemic imbalance. This class of medicine is generally used in areas where short-term symptomatic support is appropriate. In clinical practice, NSAIDs are utilized to assist with discomfort.


Core Therapeutic Areas

NSAIDs are applicable within clinical settings that involve acute or unstable symptom patterns, and are considered relevant for managing symptoms that interfere with daily comfort. This supportive relief helps ease the overall symptom burden in conditions characterized by periods of heightened symptoms. Commonly, they are applied in addressing symptom clusters that include headaches, migraines, toothache, muscular aches, and painful periods. They are also considered relevant for easing discomfort associated with inflammatory or irritative states like osteoarthritis, rheumatoid arthritis, sprains, and strains.

The goal is to provide supportive relief that helps patients cope more steadily. Supportive symptom management is appropriate in contexts involving acute or disruptive symptom patterns. This support assists with maintaining functional stability during episodes of heightened discomfort or temporary physiological imbalance.

Quick Fact: Relief for Acute Discomfort
NSAIDs may assist with symptoms that become more disruptive during flare-ups or acute episodes, supporting general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Roll (Rabeprazole)

Use of Roll is strictly defined by regulatory eligibility criteria. The medicine is contraindicated in patients with a known hypersensitivity to rabeprazole, any component of the formulation, or any other substituted benzimidazoles (the PPI class).

Age-Group Eligibility Status as Per Regulatory Documents
Adults (18+ years) Generally approved for use.
Adolescents (12+ years) Approved for specific, short-term use (e.g., GERD).
Children (under 12 years) Use is restricted by formulation; safety and efficacy are not established for infants under 1 year of age.

Condition-Based Restrictions

Official labeling requires the exclusion of gastric or esophageal malignancy before initiating treatment with Rabeprazole. Caution is also advised when the drug is first initiated in patients with severe hepatic impairment. Furthermore, use is contraindicated or not recommended for pregnant and breastfeeding individuals, based on risk assessment documented in official sources.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Roll (Rabeprazole) is principally defined by its ability to significantly reduce gastric acid, which can affect the absorption of other co-administered substances. Regulatory documents classify several critical interactions based on this mechanism.


Official Interaction Statements

Classification Interacting Substance Resulting Interaction Constraint
Contraindicated Rilpivirine-containing products Use is prohibited due to the risk of substantially decreased Rilpivirine plasma concentrations.
Decreased Exposure Ketoconazole, Itraconazole, Atazanavir, Nelfinavir Absorption is reduced, potentially compromising therapeutic efficacy. Avoidance or careful consideration is advised for Nelfinavir and Atazanavir.
Increased Exposure Digoxin, Saquinavir Plasma levels of these medicines may increase.
Pharmacodynamic/Metabolic Warfarin Monitoring of International Normalized Ratio (INR) and prothrombin time is required.
Pharmacodynamic/Metabolic Clopidogrel May decrease the pharmacological activity of Clopidogrel; the need for co-administration must be carefully considered.

Additional Constraints

Co-administration with high-dose Methotrexate is associated with elevated and prolonged serum concentrations of Methotrexate, and temporary withdrawal of Rabeprazole should be considered. Furthermore, caution is advised when initiating Rabeprazole in patients with severe hepatic dysfunction due to limited data regarding potential increased exposure in this population. No clinically significant interaction has been documented with liquid antacids.

Mechanism of Action

How Roll Works

Roll is a bisphosphonate that acts by binding with high affinity to hydroxyapatite crystals on the bone mineral surface. This localization ensures the compound is selectively internalized by active osteoclasts during the resorption process, initiating its primary inhibitory action.

Once internalized, Roll interferes with the farnesyl pyrophosphate synthase (FPPS) enzyme within the mevalonate pathway. This specific intracellular disruption prevents the post-translational lipidation of small GTPase signaling proteins, which are essential for osteoclast function. The cascade ultimately leads to the impaired ruffled border formation and suppressed resorptive capabilities of the osteoclast.

This overall cellular suppression decreases the local rate of bone resorption, contributing to an overall negative balance between the tissue-level processes of bone formation and resorption.

Dosage and Administration Information

How Roll is Used: General Administration Guidelines

Roll (Rabeprazole) is administered exclusively by the oral route as a delayed-release tablet or capsule. The specialized formulation requires strict adherence to preparation and handling constraints; the delayed-release tablets must be swallowed whole and must not be crushed, split, or chewed to ensure the integrity of the enteric coating upon ingestion.


Standard Dosing and Frequency Patterns

The standard administration pattern for most short-term approved uses, such as the healing of erosive esophagitis (EE) or symptomatic conditions, involves a dose of 20 mg taken once daily (OD). This OD regimen is also common for long-term maintenance therapy, where the dose may be reduced to 10 mg. For the specific treatment of H. pylori eradication, the established regimen requires 20 mg twice daily (BID) as a component of a multi-drug course, typically lasting seven days. In pathological hypersecretory conditions, such as Zollinger-Ellison Syndrome, initial dosing may start at 60 mg OD, with maintenance regimens that may require 60 mg BID.


Administration Conditions and Adjustments

The timing of the dose in relation to food depends on the condition being addressed: while the medicine can generally be taken with or without food, the H. pylori regimen specifically requires administration with the morning and evening meals. For pediatric patients (1–11 years), dosing is stratified by weight, using 5 mg or 10 mg OD based on whether the child is below or above 15 kg. No dosage adjustment is typically necessary for older adults or in cases of renal impairment, but caution is advised, and dose adjustment may be considered, in severe hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Roll (Rabeprazole)


Research Evidence for Healing and Maintenance of Erosive GERD

The research used to characterize Roll for cases of tissue injury in the esophagus primarily consists of short-term, defined-interval Randomized Controlled Trials (RCTs). These studies were designed to evaluate physical outcomes related to tissue changes, specifically the measurement of mucosal healing. Researchers monitored changes in the observed populations over specific periods, typically four to eight weeks.

Studies also examined the long-term use of the medicine to see if a sustained low acid environment was associated with fewer instances of tissue change or recurrence. Studies monitored patterns which suggested that patients in the research contexts reported differences in the frequency of symptom and tissue recurrence compared to those receiving placebo. Findings observed in the studies are similar to those reported across the general class of Proton Pump Inhibitor medicines. Controlled evidence for long-term outcomes remains less fully established beyond one year.


Research for Symptom Control in Non-Erosive Reflux Disease (NERD)

Roll was evaluated in research exploring short-term symptom patterns, such as heartburn, in people who have reflux but no visible tissue damage (NERD). These trials applied in studies examining patient-reported experiences, where the primary outcome was how patients reported their perceived discomfort. Studies monitored patterns of symptom score differences over defined time intervals. However, evidence derived from settings with varying symptom burdens indicates that findings were mixed, which is common in studies relying on subjective symptom reporting.


Evidence for Ulcer Healing and H. pylori Eradication

Roll was evaluated in short-term RCTs for the healing of duodenal ulcers. Furthermore, research examined the use of Roll as part of a multi-drug regimen to clear the H. pylori bacteria. The challenges associated with successful clearance is a key area addressed by subsequent research, as success is dependent on the specific antibiotic combination used and the local patterns of H. pylori resistance.


Areas of Ongoing Scientific Uncertainty

The evidence landscape highlights areas where more context is needed. Data for certain subgroups, such as individuals with significant liver impairment or complex comorbidities, may be insufficient. Also, for symptomatic conditions like NERD, high variability in patient-reported outcomes means that certainty remains low regarding how individuals may experience outcomes. Research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Roll (FAQ)

Q: Does Roll affect liver function, and how is that monitored?

Official safety information notes that caution is advised when the medicine is used by people with severe hepatic dysfunction (serious liver impairment). Although rare, reports of hepatic encephalopathy (a change in brain function due to liver disease) have been received in patients with existing cirrhosis. A healthcare professional can determine if any special monitoring related to liver function is needed.


Q: Does Roll require special lab tests or monitoring while I am using it?

The official product labeling states that monitoring of International Normalized Ratio (INR) and prothrombin time is required if taken with the medicine warfarin. For people on prolonged treatment, healthcare professionals should also consider monitoring magnesium levels. These steps help manage potential risks associated with the treatment.


Q: Why do some people report feeling better right away, and others take longer?

Clinical pharmacology studies indicate that the medicine’s primary action—the reduction of stomach acid—begins within about one hour after the first dose. However, the time it takes for tissue injuries (such as those in the esophagus) to fully heal, or for full symptom relief to be felt, is measured over several weeks. This difference between immediate acid suppression and gradual tissue healing can account for varied patient experiences.


Q: Does the efficacy of Roll vary between different groups of people (e.g., by weight or gender)?

Official information shows that dosing for children is stratified (grouped) according to their weight. Furthermore, research suggests that the medicine's effectiveness for healing tissue appears consistent regardless of a person’s body mass index (BMI). Information related to efficacy in certain complex patient groups may be less established.


Q: What is meant by a 'contraindication' for Roll?

A contraindication is a condition or circumstance that regulatory documents state indicates a circumstance where the medicine should generally not be used. For Roll, contraindications include having a known hypersensitivity (severe allergic reaction) to the drug or related compounds, or taking other specific drugs, such as products containing rilpivirine.


Q: Is it common for people to feel fatigued after starting Roll?

Regulatory safety data indicate that fatigue (asthenia) is listed in the 'common' side effect category. This means it has been reported to occur in a defined percentage of patients during clinical studies. Concerns about fatigue are typically directed to a healthcare professional.


Q: How long does it typically take before I start to notice Roll having an effect?

According to regulatory clinical information, the drug's primary action of reducing stomach acid begins within one hour after the first dose is taken. This is when the medication starts to work at a cellular level.


Q: Can I use over-the-counter pain relievers while I am taking Roll?

The official product label lists known interactions with other prescription medications, but does not list a major conflict with non-NSAID over-the-counter pain relievers like acetaminophen. All over-the-counter medicines and supplements are commonly reviewed with a healthcare professional to confirm their appropriateness.


Q: Does consuming alcohol while on Roll cause any known problems?

Official guidance from some regulatory bodies suggests that a doctor may advise a patient to limit their alcohol intake while undergoing treatment with this medication. Specific guidance from a healthcare professional is typically followed in these circumstances.


Q: Are there any herbal supplements or vitamins that should be avoided with Roll?

Regulatory sources indicate that long-term use of this medicine may affect the body’s ability to absorb Vitamin B12. Additionally, caution is advised when the drug is taken with other medicines or supplements that are known to cause low magnesium levels (hypomagnesemia). Such concerns are commonly addressed by a healthcare professional.


Q: Does Roll interact with common prescription medications like blood pressure pills or antidepressants?

Official documents mention known interactions with certain antidepressants. Furthermore, caution is advised when the drug is taken alongside diuretics (a type of blood pressure pill) because of the risk of low magnesium levels. Review of all prescription medications for potential interactions is performed by a pharmacist or doctor.


Q: Is it okay to take Roll if I have a history of heart problems?

Published observational studies have suggested that the Proton Pump Inhibitor (PPI) class of medicines may be associated with an increased risk of heart attack. Due to this potential association, discussion of any history of heart problems and overall health history with a doctor is necessary before starting or continuing the medicine.


Q: Can taking Roll make me drowsy or affect my ability to drive?

Somnolence, or drowsiness, is listed as an uncommon side effect in the safety data. If this or other effects on the nervous system occur, official guidance notes that caution is advised when performing tasks such as driving or operating machinery if these effects occur.


Q: Does Roll affect mental clarity or mood?

Official safety data includes reports of effects on the nervous and psychiatric systems. These have included instances of insomnia, nervousness, depression, confusion, and delirium. Changes in mental clarity or mood, if they occur, are typically reported to a healthcare professional.


Q: What is the expected duration of effect after a single dose of Roll?

Roll works by binding irreversibly to the proton pump enzyme, a process known as sustained inactivation. This means the medicine's effect lasts significantly longer than the short time the drug remains in the bloodstream. This prolonged action provides sustained acid suppression over a 24-hour period.


Q: What are the common signs of an allergic reaction to Roll?

Signs of a hypersensitivity reaction (severe allergic reaction) noted in regulatory documents may include anaphylaxis, angioedema (swelling), bronchospasm (difficulty breathing), and urticaria (hives). If any of these signs appear, immediate medical attention is necessary.


Q: Is Roll known to cause weight gain or loss?

Official adverse reaction reports list an increase in weight as an uncommon side effect observed in postmarketing experience. Unusual weight gain or loss has also been listed as a less common side effect. Unexplained weight changes are typically discussed with a healthcare professional.

How should Roll be stored and disposed of?

How to Store and Dispose of Roll?

Official Storage Requirements

Roll (Rabeprazole sodium) must be stored strictly according to its official labeling to maintain stability. The product must be kept at a controlled room temperature, typically defined between 20 C and 25 C (68 F and 77 F), with excursions up to 30 C permitted.

  • Protection: The medicine must be stored in its original container, kept tightly closed, and protected from both moisture and light. Do not store the medicine in high-humidity areas like the bathroom.
  • Stability: If the product is dispensed in a bottle, any unused portion must be discarded 60 days after the bottle is first opened.
  • Child Safety: Roll must be stored out of the sight and reach of children.

Disposal Instructions

Disposal must adhere to local requirements for unused or expired medicines. The product must not be thrown away via wastewater (such as flushing down a toilet or sink) or general household waste. Patients should consult their pharmacist or local regulatory body for guidance on proper pharmaceutical take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Roll found in:

A-Z Index: